Search publications

Publications

  • Xu L, Pierce JL, Sánchez A, Chen KS, Shukla AA, Fustino NJ, Stuart S, Bagrodia A, Krailo MD, Shaikh F, Billmire D, Pashankar F, Bestrashniy J, Wolter Oosterhuis J, Biermann K, Gillis AJM, Stoop J, Xie Y, Teot L, Mora J, Poyter JN, Rakheja D, Looijenga LHJ, Draper BW, Lindsay Frazier A and Armatruda JF.

    Integrated genomic analysis reveals aberrations in WNT signaling in germ cell tumours of childhood and adolescence

    EUR UROL SUPPL . 18(4): 13-14.

    [doi:10.1016/S1569-9056(19)32491-1]

  • Garcia-López M, Rodriguez-Hernandez CJ, Mateo-Lozano S, Pérez-Jaume S, Gonçalves-Alves E, Lavarino C, Mora J and de Torres C.

    Parathyroid hormone-like hormone plays a dual role in neuroblastoma depending on PTH1R expression

    MOLECULAR ONCOLOGY . 13(9): 1959-1975. Number of citations: 9

    [doi:10.1002/1878-0261.12542]

  • Mora J, Valero M, DiCristina C, Jin M, Chain A and Bickham K.

    Pharmacokinetics/pharmacodynamics, safety, and tolerability of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients

    PEDIATRIC BLOOD & CANCER . 66(6): . Number of citations: 11

    [doi:10.1002/pbc.27690]

  • Carvalho D, Taylor KR, Gene-Olaciregui N, Molinari V, Clarke M, Mackay A, Ruddle R, Henley A, Valenti M, Hayes A, Brandon AH, Eccles SA, Raynaud F, Boudhar A, Monje M, Popov S, Moore AS, Mora J, Cruz-Martínez O, Vinci M, Brennan PE, Bullock AN, Carcaboso AM and Jones C.

    ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma

    Communications Biology . 2: 156-156. Number of citations: 77

    [doi:10.1038/s42003-019-0420-8]

  • Puerto-Camacho P, Amaral AT, Lamhamedi-Cherradi SE, Menegaz BA, Castillo H, Ordóñez JL, Dominguez-Hormaetxe S, Jordan-Perez C, Diaz-Martin J, Romero-Pérez L, Lopez-Alvarez M, Civantos-Jubera G, Robles-Frias MJ, Biscuola M, Ferrer C, Mora J, Cuglievan B, Schadler KL, Seifert O, Kontermann RE, Pfizenmaier K, Simon L, Fabre M, Carcaboso AM, Ludwig JA and de Álava E.

    Preclinical Efficacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing Sarcoma

    CLINICAL CANCER RESEARCH . 25(7): 2228-2240. Number of citations: 32

    [doi:10.1158/1078-0432.CCR-18-0936]

  • Guenther LM, Dharia NV, Ross L, Saur Conway A, Robichaud AL, Catlett JL, Wechsler C, Frank ES, Goodale AB, Church AJ, Tseng YY, Guha R, McKnight C, Janeway KA, Boehm JS, Mora J, Davis MI, Alexe G, Piccioni F and Stegmaier K.

    A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma

    CLINICAL CANCER RESEARCH . 25(4): 1343-1357. Number of citations: 69

    [doi:10.1158/1078-0432.CCR-18-0372]

  • Pascual-Pastó G, Bazan-Peregrino M, Gene-Olaciregui N, Restrepo-Perdomo CA, Mato-Berciano A, Ottaviani D, Weber K, Correa MG, Paco-Mercader S, Vilà-Ubach M, Cuadrado-Vilanova M, Castillo H, Botteri G, García-Gerique L, Moreno-Gilabert H, Gimenez-Alejandre M, Alonso-Lopez P, Farrera-Sal M, Torres-Manjon S, Ramos-Lozano D, Moreno R, Aerts I, Doz F, Cassoux N, Chapeaublanc E, Torrebadell-Burriel M, Roldan-Molina M, König A, Suñol M, Claverol J, Lavarino C, de Torres C, Fu L, Radvanyi F, Munier FL, Català-Mora J, Mora J, Alemany R, Cascallo M, Chantada G and Carcaboso AM.

    Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01

    SCIENCE TRANSLATIONAL MEDICINE . 11(476): 9321. Number of citations: 86

    [doi:10.1126/scitranslmed.aat9321]

  • Reichardt P, Tabone MD, Mora J, Morland B and Jones RL.

    Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling

    FUTURE ONCOLOGY . 14(25): 2663-2676. Number of citations: 120

    [doi:10.2217/fon-2018-0210]

  • Pishas KI, Drenberg CD, Taslim C, Theisen ER, Johnson KM, Saund RS, Pop IL, Crompton BD, Lawlor ER, Tirode F, Mora J, Delattre O, Beckerle MC, Callen DF, Sharma S and Lessnick SL.

    Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response

    MOLECULAR CANCER THERAPEUTICS . 17(9): 1902-1916. Number of citations: 46

    [doi:10.1158/1535-7163.MCT-18-0373]

  • Garcia-Monclus S, Lopez-Alemany R, Almacellas-Rabaiget O, Herrero-Martin D, Huertas-Martinez J, Lagares-Te L, Alba-Pavon P, Hontecillas-Prieto L, Mora J, de Alava E, Rello-Varona S, Giangrande PH and Tirado OM.

    EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma

    INTERNATIONAL JOURNAL OF CANCER . 143(5): 1188-1201. Number of citations: 50

    [doi:10.1002/ijc.31405]